Update on vasculitis

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 6, 2009, Pages 1226-1236

  Khasnis, Atul ^a   Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

antineutrophil cytoplasmic antibodies; diagnosis; treatment; Vasculitis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTOXIFYLLINE; PREDNISONE; RITUXIMAB; ULINASTATIN; ANTIHISTAMINIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ACNE; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ARTICLE; AVASCULAR NECROSIS; BLADDER CANCER; BONE MARROW TOXICITY; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CORONARY ARTERY ANEURYSM; DISEASE CLASSIFICATION; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFERTILITY; INTERSTITIAL PNEUMONIA; LEUKEMIA; LIVER TOXICITY; LONG TERM CARE; LUNG FIBROSIS; LYMPHOMA; MICROSCOPIC POLYANGIITIS; MOOD CHANGE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; OSTEOPOROSIS; PATHOGENESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SIDE EFFECT; STRIA; SYSTEMIC VASCULITIS; TERATOGENICITY; VASCULITIS; WEGENER GRANULOMATOSIS; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; ANGIOGRAPHY; BLOOD; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; IMMUNOLOGY; REVIEW;

ANGIOGRAPHY; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS;

EID: 67649183669     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.04.024     Document Type: Article

References (83)

1. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell (temporal) arteritis. Arthritis Rheum 33 (1990) 1122-1128
2. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
3. Sneller M.C., and Fauci A.S. Pathogenesis of vasculitis syndromes. Med Clin North Am 81 (1997) 221-242
4. Cid M.C., and Vilardell C. Tissue targeting and disease patterns in systemic vasculitis. Best Pract Res Clin Rheumatol 15 (2001) 259-279
5. Davies D.J., Moran J.E., Niall J.F., and Ryan G.B. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus etiology?. BMJ 285 (1982) 606
6. Falk R.J., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318 (1988) 1651-1657
7. Kallenberg C.G.M. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
8. van der Woude F.J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L.A., et al. Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 2 (1985) 425-429
9. Langford C.A. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Cleve Clin J Med 65 (1998) 135-140
10. Finkielman J.D., Merkel P.A., Schroeder D., Hoffman G.S., Spiera R., St Clair E.W., et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147 (2007) 611-619
11. Kerr G.S., Fleisher T.A., Hallahan C.W., Leavitt R.Y., Fauci A.S., and Hoffman G.S. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 36 (1993) 365-371
12. Girard T., Mahr A., Noël L.H., Cordier J.F., Lesavre P., André M.H., et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 40 (2001) 147-151
13. Boomsma M.M., Stegeman C.A., van der Leij M.J., Oost W., Hermans J., Kallenberg C.G., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43 (2000) 2025-2033
14. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58 (2008) 26-35
15. Klein R.G., Hunder G.G., Stanson A.W., and Sheps S.G. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 83 (1975) 806-812
16. Evans J.M., Bowles C.A., Bjornsson J., Mullany C.J., and Hunder G.G. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 37 (1994) 1539-1547
17. Achkar A.A., Lie J.T., Hunder G.G., O'Fallon W.M., and Gabriel S.E. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med 120 (1994) 987-992
18. Karassa F.B., Matsagas M.I., Schmidt W.A., and Ioannidis J.P. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 142 (2005) 359-369
19. Salvarani C., Silingardi M., Ghirarduzzi A., Lo Scocco G., Macchioni P., Bajocchi G., et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. Ann Intern Med 137 (2002) 232-238
20. Aiello P.D., Trautmann J.C., McPhee T.J., Kunselman A.R., and Hunder G.G. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
21. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., and Sonnenblic M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
22. Lee M.S., Smith S.D., Galor A., and Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
23. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
24. Jover J.A., Hernández-García C., Morado I.C., Vargas E., Bañares A., and Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
25. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
26. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu arteritis. Ann Intern Med 120 (1994) 919-929
27. Hoffman G.S., Leavitt R.Y., Kerr G.S., Rottem M., Sneller M.C., and Fauci A.S. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37 (1994) 578-582
28. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
29. Knight A., Sandin S., and Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 58 (2008) 302-307
30. Cotch M.F., Hoffman G.S., Yerg D.E., Kaufman G.I., Targonski P., and Kaslow R.A. The epidemiology of Wegener's granulomatosis. Arthritis Rheum 39 (1996) 87-92
31. Merkel P.A., Lo G.H., Holbrook J.T., Tibbs A.K., Allen N.B., Davis Jr. J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142 (2005) 620-626
32. Sebastian J.K., Voetsch B., Stone J.H., Romay-Penabad Z., Lo G.H., Allen N.B., et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 34 (2007) 2446-2450
33. Finkielman J.D., Lee A.S., Hummel A.M., Viss M.A., Jacob G.L., Homburger H.A., et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 120 (2007) 643 e9-e14
34. Fauci A.S., and Wolff S.M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 52 (1973) 535-561
35. Fauci A.S., Haynes B.F., Katz P., and Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98 (1983) 76-85
36. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42 (1999) 2666-2673
37. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniené J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
38. Langford C.A., Talar-Williams C., and Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51 (2004) 278-283
39. Metzler C., Fink C., Lamprecht P., Gross W.L., and Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43 (2004) 315-320
40. Sneller M.C., Hoffman G.S., Talar-Williams C., Kerr G.S., Hallahan C.W., and Fauci A.S. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38 (1995) 608-613
41. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
42. Molloy E.S., and Langford C.A. Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?. Nat Clin Pract Rheumatol 4 (2008) 12-13
43. Stegeman C.A., Tervaert J.W., de Jong P.E., and Kallenberg C.J. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335 (1996) 16-20
44. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 (2007) 2180-2188
45. Langford C.A., Sneller M.C., Hallahan C.W., Hoffman G.S., Kammerer W.A., Talar-Williams C., et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 39 (1996) 1754-1760
46. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
47. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
48. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
49. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
50. Guillevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 (1999) 421-430
51. Agard C., Mouthon L., Mahr A., and Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: how and when do they start?. Arthritis Rheum 49 (2003) 709-715
52. Bourgarit A., Le Toumelin P., Pagnoux C., Cohen P., Mahr A., and Le Guern V. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84 (2005) 323-330
53. Lhote F., Cohen P., Généreau T., Gayraud M., and Guillevin L. Microscopic polyangiitis: clinical aspects and treatment. Ann Med Interne (Paris) 147 (1996) 165-177
54. Lanham J.G., Elkon K.B., Pusey C.D., and Hughes G.R. Systemic vasculitis with asthma and eosinophilia: a clinical approach to Churg-Strauss syndrome. Medicine 63 (1984) 65-81
55. Mahr A., Guillevin L., Poissonnet M., and Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51 (2004) 92-99
56. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., and Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 (1999) 26-37
57. Jeong Y.J., Kim K.I., Seo I.J., Lee C.H., Lee K.N., Kim K.N., et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics 27 (2007) 617-637
58. Davies D.J. Small vessel vasculitis. Cardiovasc Pathol 14 (2005) 335-346
59. Nathani N., Little M.A., Kunst H., Wilson D., and Thickett D.R. Churg Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 63 (2008) 847-849
60. Keogh K.A., and Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 27 (2006) 148-157
61. Stone J.H. Polyarteritis nodosa. JAMA 288 (2002) 1632-1639
62. Stanson A.W., Friese J.L., Johnson C.M., McKusick M.A., Breen J.F., Sabater E.A., et al. Polyarteritis nodosa: spectrum of angiographic findings. Radiographics 21 (2001) 151-159
63. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 (1996) 17-28
64. Guillevin L., Lhote F., Cohen P., Jarrousse B., Lortholary O., Généreau T., et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38 (1995) 1638-1645
65. Guillevin L., Mahr A., Callard P., Godmer P., Pagnoux C., Leray E., et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84 (2005) 313-322
66. Carlson J.A., Ng B.T., and Chen K.R. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 27 (2005) 504-528
67. Gorevic P.D., Kassab H.J., Levo Y., Kohn R., Meltzer M., Prose P., et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69 (1980) 287-308
68. Saadoun D., Delluc A., Piette J.C., and Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20 (2008) 23-28
69. Taubert K.A., Rowley A.H., and Shulman S.T. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 119 (1991) 279-282
70. Nakamura Y., Aso E., Yashiro M., Uehara R., Watanabe M., Oki I., et al. Mortality among persons with a history of Kawasaki disease in Japan: mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J 72 (2008) 134-138
71. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114 (2004) 1708-1733
72. Dajani A.S., Taubert K.A., Gerber M.A., Shulman S.T., Ferrieri P., Freed M., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 87 (1993) 1776-1780
73. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 (1991) 1633-1639
74. Durongpisitkul K., Gururaj V.J., Park J.M., and Martin C.F. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96 (1995) 1057-1061
75. McMorrow Tuohy A.M., Tani L.Y., Cetta F., Lewin M.B., Eidem B.W., Van Buren P., et al. How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease?. Am J Cardiol 88 (2001) 328-330
76. Saulsbury F.T. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 78 (1999) 395-409
77. Meadow S.R., Glasgow E.F., White R.H.R., Moncrieff M.W., Cameron J.S., and Ogg C.S. Schonlein-Henoch nephritis. QJM 41 (1972) 241-258
78. Cream J.J., Gumpel J.M., and Peachey R.D.G. Schonlein-Henoch purpura in the adult. QJM 39 (1970) 461-484
79. Tancrede-Bohin E., Ochonisky S., Vignon-Pennamen M.D., Flageul B., Morel P., et al. Schonlein-Henoch purpura in adult patients. Arch Dermatol 133 (1997) 438-442
80. Shrestha S., Sumingan N., Tan J., Alhous H., McWilliam L., and Ballardie F. Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM 99 (2006) 253-265
81. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90 (2005) 916-920
82. Schwartz H.R., McDuffie F.C., Black L.F., Schroeter A.L., and Conn D.L. Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease. Mayo Clin Proc 57 (1982) 231-238
83. Tosoni C., Lodi-Rizzini F., Cinquini M., Pasolini G., Venturini M., Sinico R.A., et al. A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients. Clin Exp Dermatol 34 (2009) 166-170